公开(公告)号：US09102653B2

公开(公告)日：2015-08-11

申请号：US14322165

申请日：2014-07-02

Applicant: NOVARTIS AG

Inventor： Timothy John Ritchie ,  Andrew James Culshaw ,  Christopher Thomas Brain ,  Edward Karol Dziadulewicz ,  Terance William Hart

IPC: C07D239/91 ,  C07D401/04

CPC classification number: C07D401/04 ,  C07D239/91

Abstract: The present specification relates to the use of a quinazolinone compound of the formula (I) wherein R1, R2, R3, R4, R5 and m are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in acid addition salt form.

Abstract translation: 本说明书涉及式（I）的喹唑啉酮化合物的用途，其中R 1，R 2，R 3，R 4，R 5和m如说明书和权利要求中所定义，为游离形式或盐形式， 在可能的情况下，以酸加成盐形式。

公开(公告)号：US20180155351A1

公开(公告)日：2018-06-07

申请号：US15886014

申请日：2018-02-01

Applicant: Novartis AG ,  Astex Therapeutics Ltd.

Inventor： Gilbert Besong ,  Christopher Thomas Brain ,  Clinton A. Brooks ,  Miles Stuart Congreve ,  Claudio Dagostin ,  Guo He ,  Ying Hou ,  Steven Howard ,  Yue Li ,  Yipin Lu ,  Paul Mortenson ,  Troy Smith ,  Moo Je Sung ,  Steven Woodhead ,  Wojciech Wrona ,  Bharat Lagu

IPC: C07D487/04 ,  A61K31/519

CPC classification number: C07D487/04 ,  A61K31/519 ,  C07D487/08

Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.

公开(公告)号：US20180207163A1

公开(公告)日：2018-07-26

申请号：US15935294

申请日：2018-03-26

Applicant: Novartis AG

Inventor： Maria Borland ,  Christopher Thomas Brain ,  Shivang Doshi ,  Sunkyu Kim ,  Jianguo Ma ,  Josh Murtie ,  Hong Zhang

IPC: A61K31/519 ,  A61K31/436 ,  A61K45/06

CPC classification number: A61K31/519 ,  A61K31/436 ,  A61K45/06 ,  A61K2300/00

Abstract: A combination of a CDK4/6 inhibitor and an mTOR inhibitor for the treatment of cancer.

公开(公告)号：US08962630B2

公开(公告)日：2015-02-24

申请号：US13786955

申请日：2013-03-06

Applicant: Novartis AG ,  Astex Therapeutics

Inventor： Christopher Thomas Brain ,  Moo Je Sung ,  Bharat Lagu

IPC: C07D487/04 ,  A61K31/519 ,  A61P35/00 ,  A61P35/04 ,  A61P35/02 ,  C07D487/08

CPC classification number: C07D487/04 ,  A61K31/519 ,  C07D487/08

Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.

Abstract translation: 所公开的化合物涉及蛋白激酶相关病症的治疗和疗法。 还需要可用于治疗或预防或改善癌症，移植排斥和自身免疫性疾病的一种或多种症状的化合物。 此外，需要使用本文提供的化合物调节蛋白激酶如CDK1，CDK2，CDK4，CDK5，CDK6，CDK7，CDK8和CDK9的活性的方法。